Biological basis of generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 3, 1997, Pages 16-26

  Brawman Mintzer, Olga ^a   Lydiard, R Bruce ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ANXIOLYTIC AGENT; BUSPIRONE; CARBON DIOXIDE; CATECHOLAMINE; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR; DIAZEPAM; GEPIRONE; GROWTH HORMONE; HYDROCORTISONE; IPSAPIRONE; LACTATE SODIUM; ONDANSETRON; RITANSERIN; SERAZEPINE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; BRAIN BLOOD FLOW; BRAIN METABOLISM; CARBON DIOXIDE BREATHING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRACEREBRAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCUS CERULEUS; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW; STRESS;

ANXIETY DISORDERS; CARBON DIOXIDE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MODELS, BIOLOGICAL; MODELS, NEUROLOGICAL; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PANIC DISORDER; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES; SODIUM LACTATE; TERMINOLOGY;

EID: 0030898762     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Rapee RM. Generalized anxiety disorder: a review of clinical features and theoretical concepts. Clinical Psychology Review 1991;11: 419-440
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Press; 1994
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
4. Brawman-Mintzer O, Lydiard RB, Crawford M, et al. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry 1994;151:930-932
5. Marten PA, Brown TA, Barlow DH, et al. Evaluation of the ratings comprising the associated symptom criterion of DSM-III-R generalized anxiety disorder. J Nerv Ment Dis 1993;181:676-682
6. Blazer DG, Hughes D, George LK, et al. Generalized anxiety disorder. In: Robins LN, Reiger DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991: 180-203
7. Faravelli C, Deglinnocenti BG, Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 1989;79:308-312
8. Wacker HR, Mullejans R, Klein KH, et al. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R using the Composite International Diagnostic Interview (CIDI). International Methods in Psychiatric Research 1992;2:91-100
9. Kessler RC, McGobagle KA, Zhao S, et al. Lifetime and 2-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
10. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
11. Brawman-Mintzer O, Lydiard RB, Emmanuel NP, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993; 150:1216-1218
12. Torgersen S. Genetic factors in anxiety disorder. Arch Gen Psychiatry 1983;40:1085-1089
13. Andrews G, Stewart S, Allen R, et al. The genetics of six neurotic disorders: a twin study. J Affect Disord 1990;19:23-29
14. Noyes R, Clarkson C, Crowe RR, et al. A family study of generalized anxiety disorder. Am J Psychiatry 1987;144:1019-1024
15. Skre I, Torgersen S, Lygren S, et al. A twin study of DSM-III-R anxiety disorders. Acta Psychiatr Scand 1993;88:85-92
16. Kendler KS, Neale MC, Kessler RC, et al. Generalized anxiety disorder in women. Arch Gen Psychiatry 1992;49:267-272
17. Kendler KS, Neale MC, Kessler RC, et al. Major depression and generalized anxiety disorder. Arch Gen Psychiatry 1992;49:716-722
18. Chrousos GP, Gold PW. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 1992;267: 1244-1252
19. Mathew RJ, Ho BT, Kralik P, et al. Catechol-O-methyltransferase and catecholamines in anxiety and relaxation. Psychiatry Res 1980;3:85-91
20. Mathew RJ, Ho BT, Francis DJ, et al. Catecholamines and anxiety. Acta Psychiatr Scand 1982;65:142-147
21. Munjack DJ, Baltazar PL, DeQuattro V, et al. Generalized anxiety disorder: some biochemical aspects. Psychiatry Res 1990;32:35-43
22. Khan A, Lee E, Dager S, et al. Platelet MAO-B activity in anxiety and depression. Biol Psychiatry 1986;21:847-849
23. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991;25:141-152
24. Sevy S, Papadimitriou GN, Surmont DW, et al. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989;25:141-152
25. 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 1990;28:3-20
26. Charney DS, Woods SW, Heninger GR. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 1989;27:173-182
27. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991; 12:118-134
28. Curtis G, Fogel M, McEvoy D, et al. Urine and plasma corticosteroids, psychological tests, and effectiveness of psychological defenses. J Psychiatr Res 1970;7:237-247
29. Rosenbaum AH, Schatzberg AF, Jost FA, et al. Urinary free cortisol levels in anxiety. Psychosomatics 1983;24:835-837
30. Avery DH, Osgodd TB, Ishiki DM, et al. The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am J Psychiatry 1985;142:844-848
31. Tiller JWG, Biddle N, Maguire KP, et al. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 1988;23:261-270
32. Munjack DJ, Palmer R. Thyroid hormones in panic disorder, panic disorder with agoraphobia, and generalized anxiety disorder. J Clin Psychiatry 1988;49:229-231
33. Hoehn-Saric R, McLeod DR, Zimmerli WD. Somatic manifestations in women with generalized anxiety disorder. Arch Gen Psychiatry 1989; 46:1113-1119
34. Cowley DS, Dager SR, McClellan J, et al. Response to lactate infusion in generalized anxiety disorder. Biol Psychiatry 1988;24:409-414
35. Gorman J, Fyer M, Goetz R, et al. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988;45:31-39
36. Holt P, Andrews G. Provocation of panic: three elements of the panic reaction in four anxiety disorders. Behav Res Ther 1989;27:253-261
37. Rapee RM, Brown TA, Antony MM, et al. Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III-R anxiety disorders. J Abnorm Psychol 1992;101:538-552
38. Verburg K, Griez E, Meijer J, et al. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiatry 1995;152:1081-1083
39. Weizman R, Tanne Z, Granek M, et al. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 1987;138:289-292
40. Ferrarese C, Appollonio I, Frigo M, et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 1990;82:169-173
41. Rocca P, Ferrero P, Gualerzi A, et al. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr Scand 1991;84:537-544
42. Roy-Byrne PP, Cowley DS, Greenblatt DJ, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:534-538
43. Cowley DS, Roy-Byrne PP, Hommer D, et al. Benzodiazepine sensitivity in anxiety disorders. Biol Psychiatry 1991;29:57A
44. Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks. Arch Gen Psychiatry 1990;47:917-925
45. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995;56(2, suppl):38-48
46. 2) mediation of anxiety: therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry 1993;34:41-44
47. Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10(suppl):26-30
48. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979;18:689-695
49. Engel JA, Hjorth S, Svensson K, et al. Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2(di-n-propylamino)tetraline (8-OH-DPAT). Eur J Pharmacol 1984;105:365-368
50. VanderMaelen CP, Matheson KG, Wilderman RG, et al. Inhibition of serotonergic dorsal rapine neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 1986;129:123-130
51. 1A agonist gepirone: electrophysiological studies in rat brain. Synapse 1987;1:470-480
52. Graeff FG. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briley M, File S, eds. New Concepts in Anxiety. London, England: MacMillan Press; 1991
53. Germine M, Goddard AW, Woods SW, et al. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992;32:457-461
54. 2 receptor sensitivity in generalized anxiety disorder: a pilot study with ritanserin. Psychopharmacology (Berl) 1992;108:387-389
55. Brewerton TD, Lydiard RB, Johnson MR, et al. CSF serotonin: diagnostic and seasonal differences. In: New Research and Abstracts of the 148th Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR385:151
56. 3H) paroxetine binding on human platelets. Society Biological Psychiatry; 1994
57. Butler PD, Nemeroff CB, Chappell. Corticotropin-releasing factor as a possible cause of comorbidity in anxiety and depressive disorders. In: Maser CR, Cloninger CR, eds. Comorbidity of Mood Disorders. Washington, DC: American Psychiatric Press; 1990
58. Swerdlow NR, Geyer MA, Vale WW, et al. Corticotropin-releasing factor potentials acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) 1986;88:147-152
59. Fossey MD, Lydiard RB, Laraia MT, et al. CSF corticotropin-releasing factor (CRF) in patients with anxiety disorders. Presented at the Society of Biological Psychiatry Annual Meeting; May 12, 1990; New York, NY
60. Lydiard RB. Neuropeptides and anxiety: focus on cholecystokinin. Clin Chem 1994;40:315-318
61. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. TIPS 1993;14:244-249
62. Csonka E, Fekete M, Nagy G, et al. Anxiogenic effect of cholecystokinin in rats. In: Penke B, Torok A, eds. Peptides. New York, NY: Walter de Gruyter; 1988:249-252
63. Maeda H, Maki S, Uchimura H. Faciliatory effects of cerulean on hypothalamic defensive attack in cats. Brain Res 1988;459:351-355
64. Woodruff GN, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991;31:469-501
65. Philipp E, Wilckens T, Friess E, et al. Cholecystokinin, gastrin and stress hormone responses in marathon runners. Peptides 1992;13:125-128
66. Bradwejn J, Koszycki D, Couetoux du Tertre A, et al. The cholecystokinin hypothesis of panic and anxiety disorders: a review. Journal of Psychopharmacology 1992;6:345-351
67. B agonist challenge. Presented at the 15th National Conference of the Anxiety Disorders Association of America; April 19-21, 1995; Pittsburgh, Pa
68. Lauer G, Arnold R, Monnikes H. CCK induces C-Fos Expression in the locus coeruleus (LC), the nucleus of the solitary tract (NTS) and the hypothalamic paraventricular nucleus (PVN) via CCK-A-receptors and capsaicin-sensitive vagal pathways. In: Grundy D, Wingate D, eds. Neurogastroenterology and Motility. Osney Mead, Oxford, United Kingdom: Blackwell Science; 1995
69. Bradwejn J, Koszycki D, Couetoux du Tertre A, et al. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology (Berl) 1994;114:257-261
70. 3 receptors, antagonizes the antiexploratory effects of cerulein, an antagonist of CCK receptors, in the elevated plusmaze. Psychopharmacology (Berl) 1993;110:213-221
71. Abelson JL, Nesse RM, Vinik AI. Pentagastrin infusions in patients with panic disorder, II: neuroendocrinology. Biol Psychiatry 1994;36:84-96
72. Kamilaris TC, Johnson EO, Calogero AK, et al. Cholecystokinin-octapeptide stimulates hypothalmic-corticotropin-releasing hormone. Endocrinology 1992;130:1764-1774
73. B receptors in behavioural and hormonal studies in rats. Arch Pharm 1994;349:478-484
74. Mathew RJ, Weinman ML, Claghorn JL. Anxiety and cerebral blood flow. In: Mathew RJ, ed. The Biology of Anxiety. New York, NY: Brunner/ Mazel; 1982
75. Gur RC, Gur RE, Resnick SM, et al. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab 1987;7:173-177
76. Wu JC, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol Psychiatry 1991;29:1181-1199
77. 2 in anxiety. Psychiatry Res 1987;23:285-294
78. Gray JA. The neuropsychological basis of anxiety. In: Last CG, Hersen M, eds. Handbook of Anxiety Disorders. New York, NY: Pergamon Press; 1988;10-37